HCPLive

The latest edition of the Provider's Digest, HCPLive's monthly newsletter spotlighting regulatory decisions and pipeline news, is now live! In our November 2024 recap, we spotlight 24 pieces of pipeline news, including 12 FDA decisions and 12 announcements of other regulatory updates. Be sure to subscribe for a recap of the therapies, companies, and individuals moving the needle in healthcare during the past month, delivered on the first Saturday of each new month! Want to hear from the experts? Look for our Related Content links underneath blurbs for insight into how this decision might influence practice moving forward.

Navacaprant, a novel kappa opioid receptor antagonist, did not significantly improve depression symptoms in adults with major depressive disorder (MDD), missing the primary endpoint of the Phase 3 KOASTAL-1 trial. Neumora Therapeutics announced navacaprant continues to be studied in ongoing trials (KOASTAL-2, KOASTAL-3, KOASTAL-LT) in adults with MDD. 🔗 https://lnkd.in/eJZeSP3u #Psychiatry #Depression #MajorDepressiveDisorder

Learn how Dr. Irina Sobol, cardiologist and medical director of the LVAD program at NewYork-Presbyterian and Weill Cornell Medicine, believes in the power of empathy. See how her relationship-centric approach helped guide a hesitant cardiac patient to a life-saving left ventricular assist device (LVAD) surgery. Watch the video: https://bit.ly/41ZwaT8 #sponsored

The rapid level of enrollment in a recent psoriasis study highlights that intentional and strategic approaches to trial design and conduct can lead to greater participation and retention of participants with skin of color. This ad hoc quality improvement assessment of the VISIBLE study was authored in part by Andrew Alexis, MD, MPH, of Weill Cornell Medicine’s Department of Dermatology in New York. View more on these findings here: https://https://lnkd.in/eVmHBke9

So much has happened within medicine in this past year, it's nearly impossible to keep up. So, we did it for you! Check out the headlines that defined healthcare in our #ThisYearInMedicine series! 🔗 https://lnkd.in/eEm5n3aT

Ophthalmology achieved groundbreaking advancements in 2024, with innovative therapies and cutting-edge technologies reshaping care for some of the most challenging eye conditions. These advancements highlight an exciting future for ophthalmology, with patient-centric approaches driving progress in vision preservation and restoration. Take a look back at some of our top coverage in ophthalmology from 2024! 🔗 https://lnkd.in/edHfX45h

ICYMI: To celebrate the end of 2024, we asked a group of leading experts in cardiology what storyline they think defined the year for their specialty. Check out the preview to hear from HCPLive Cardiology advisory board member and immediate past president of the Academy of Physician Associates In Cardiology Viet Le, PA-C, DMSc, of Intermountain Health, and use the link below for more! 🔗 https://lnkd.in/egVStxfw #Cardiology #Healthcare 

In the fourth and final segment from our #KidneyCompassepisode on the PARASOL Initiative, Laura Mariani, MD, MS and Prof. Daniel Gale discuss the next steps for transforming drug development in focal segmental glomerulosclerosis (FSGS) with hosts Brendon L Neuen, MBBS, PhD, of the The George Institute for Global Health and Royal North Shore Hospital, and Shikha Wadhwani, MD, MS, of The University of Texas Medical Branch. Key takeaways: 🔑 Proteinuria reduction—even without full remission—could serve as a meaningful measure for drug approval. 🔑 Addressing podocyte dysfunction is key to designing effective therapies. 🔑 Collaborative, specimen-banking trial designs are critical for biomarker discovery and validating surrogate endpoints. https://lnkd.in/efJfpFXj #Nephrology #ClinicalTrials NephCure

This year, HCPLive continued to deliver cutting-edge insights on pressing topics in healthcare, from thought-provoking discussions on the latest advancements to perspectives on health issues. Check out some of our top podcast episodes in 2024! 🔗 https://lnkd.in/eRrrrxu5

At the 22nd Annual World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Schafer Boeder, MD, UC San Diego, describes the potential role and safety of adjunctive therapy, including SGLT2 inhibitors and GLP-1 agonists, for patients with type 1 diabetes (T1D). 🔗 https://lnkd.in/eeBTSFPW #22WCIRDC #WCIRDC2024